# Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

> **NCT01332721** · PHASE1 · COMPLETED · sponsor: **Tracon Pharmaceuticals Inc.** · enrollment: 38 (actual)

## Conditions studied

- Adult Solid Tumor

## Interventions

- **DRUG:** TRC105 and Bevacizumab

## Key facts

- **NCT ID:** NCT01332721
- **Lead sponsor:** Tracon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-09
- **Final completion:** 2013-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01332721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01332721, "Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01332721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*